ArticleScientific reports2019
Immunosuppression Reduces Lung Injury Caused by Mycoplasma pneumoniae Infection.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 41 citations in OpenAlex.
- Neutrophils promote endothelial cell activation in pediatric Mycoplasma pneumoniae pneumonia.JCI insight · 2026Article
- Multi-Omics Profiling Identifies Immune-Metabolic Signatures and Gut Microbial Biomarkers in a Murine Model ofBiology · 2026Article
- Label-free Raman spectroscopic imaging enables high-content molecular phenotyping of respiratory diseases from bronchoalveolar lavage fluid.Journal of translational medicine · 2026Article
- Severe Mycoplasma pneumoniae Pneumonia During the 2023-2024 European Re-Emergence: Why Severity Does Not Predict Macrolide Resistance.Antibiotics (Basel, Switzerland) · 2026Article
- Nonlinear age-season dynamics and macrolide resistance of Mycoplasma pneumoniae: a large pediatric cohort study during the post-pandemic resurgence.BMC infectious diseases · 2026Article
- Clinical efficacy comparison of Doxycycline versus Azithromycin combined with Methylprednisolone in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Risk factors and prediction models for bronchitis obliterans after severe Mycoplasma pneumoniae pneumonia with plastic bronchitis in children.Pakistan journal of medical sciences · 2026Article
- [A prediction model for refractory pneumonia in children based on early lung ultrasound findings].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Immune Dysregulation and Cytokine Profiling in AcuteMicroorganisms · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- The predictive accuracy of systemic immune-inflammation index and lymphocyte-to-monocyte ratio for extrapulmonary complications in pediatricTranslational pediatrics · 2025Article
- Prevalence and Risk Factors of Mycoplasma Hyopneumoniae in Swine Farms, Mainland China, 2003-2024: A Meta-Analysis.Veterinary sciences · 2025Article
- Article
- Immunological landscape of children with Mycoplasma pneumoniae pneumonia in the post-COVID-19 era reveals distinctive severity indicators.Respiratory research · 2025Article
- Pulmonary embolism complicatingFrontiers in pediatrics · 2025Article
- Impact of doxycycline on mycoplasma pneumonia treatment and cancer prognosis in pediatric leukemia patients post-chemotherapy: a target trial emulation.American journal of cancer research · 2025Article
- Effects of azithromycin on lung oxidative injury and immune function in mice infected withCentral-European journal of immunology · 2025Article
- Review
- Single-cell transcriptome atlas revealed bronchoalveolar immune features related to disease severity in pediatricMedComm · 2024Article
- Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrentWorld journal of clinical cases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The underlying mechanisms of Mycoplasma pneumoniae pneumonia (MPP) pathogenesis are not clearly understood. This study aimed to investigate the correlation between immune response and lung injury in MPP. The clinical characteristics of MPP were compared between patients treated with and without immunosuppressive chemotherapy, and demographic, clinical, and laboratory data were compared between patients with severe and mild MPP. To determine the effect of immune response on lung lesions, mouse MPP and immunosuppression models were established by intranasal inoculation of M129 and intraperitoneal injection of cyclophosphamide, respectively. Myeloperoxidase and oxidant-antioxidant enzyme activities were evaluated for mechanism studies. The immunosuppressant group had a lower incidence of MPP and fewer cases of severe MPP than the non-immunosuppressant group. The severe MPP group had a greater incidence of severe immune disorders than the mild MPP group. Relative to immunosuppressed mice, wild mice exhibited more severe inflammatory infiltration and lung injury as well as a significant increase in myeloperoxidase and malondialdehyde levels and a decrease in superoxide dismutase level after MP infection. In conclusion, immunological responses likely play a vital role in MPP pathogenesis. Lung injury occurring after MP infection-which might be caused by oxidant-antioxidant imbalance-can be reduced by immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.